Table 4. Multivariate analyses of OS, DFS and PFS in relation to clinical parameters and HE4 serum levels (A, entire cohort of EC patients; B, poorly differentiated EC patients).

	OS			DFS			PFS
Variable	HR	95% CI	P-value	HR	95% CI	P-value	HR	95% CI	P-value
(A)
Lymph node involvement
Positive vs negative	0.67	0.07–6.11	0.72	1.20	0.14–10.26	0.87	0.53	0.06–5.06	0.58
Histological type
Non-endometrioid vs endometrioid	4.89	1.09–21.81	0.01	2.37	0.64–8.75	0.22	3.30	0.80–13.56	0.04
FIGO stage
III+IV vs I+II	20.32	1.79–230.40	0.04	3.84	0.44–33.47	0.20	11.72	1.13–121.31	0.09
HE4 serum levels (tertiles)
High vs low	2.84	0.54–15.01	0.22	2.80	0.65–12.15	0.17	2.76	0.47–16.14	0.26
Medium vs low	5.35	0.80–35.67	0.08	3.05	0.69–13.51	0.14	3.18	0.53–19.17	0.21
(B)
Lymph node involvement
Positive vs negative	0.55	0.05–5.58	0.62	1.32	0.14–12.30	0.81	0.54	0.05–6.08	0.62
Histological type
Non-endometrioid vs endometrioid	1.06	0.21–5.29	0.04	0.75	0.16–3.55	0.31	0.98	0.22–4.39	0.07
FIGO stage
III+IV vs I+II	14.38	1.13–183.28	0.94	3.36	0.32–35.47	0.71	10.06	0.81–125.71	0.98
HE4 serum levels (tertiles)
High vs low	6.85	1.02–46.17	0.04	17.00	1.89–153.24	0.01	9.81	1.01–95.26	0.04
Medium vs low	4.98	0.80–31.06	0.08	5.10	0.50–51.00	0.17	6.74	0.72–62.54	0.09

Abbreviations: CI=confidence interval; DFS=disease-free survival; EC=endometrial carcinoma; FIGO=International Federation of Gynecology and Obstetrics; HE4=human epididymis protein 4; HR=hazards ratio; OS=overall survival; PFS=progression-free survival; WHO=World Health Organisation.